Psychiatry

The COVID-19 pandemic has impacted exercise in a number of ways. Gyms closed, sports were cancelled, and stress rose. In absence of routine, many began to get creative…

A cohort study of patients with psoriasis found that discordance in physician and patient disease severity assessments was associated with poorer mental health status. “Although data are limited…

The immediate release d-MPH treatment is indicated for ADHD patients at least 6 years old. The US Food and Drug Administration (FDA) has approved serdexmethylphenidate (SDX) and dexmethylphenidate…

Researchers are now worried post-traumatic stress disorder (PTSD) rates may rise in patients infected with the coronavirus disease 2019 (COVID-19). A team, led by Delfina Jahiri, MD, Department…

While schizophrenia treatment has evolved from symptom reduction and relapse prevention to functional recovery in recent years, the recovery rates remain low. However, identifying variables linked to the…

While the coronavirus disease 2019 (COVID-19) pandemic has increased the stress and anxiety for virtually everyone across the globe, a select few particularly prone to heightened anxiety may…

Maternal psychiatric conditions could forecast the likelihood the offspring will develop attention deficit/hyperactivity disorder (ADHD) in late adolescence, according to new research. A team, led by Getinet Ayano,…

New research sheds light on the link between polygenic genetic risk scores (PRS) and certain symptoms associated with attention deficit/hyperactivity disorder (ADHD). A team, led by Isabella Vainieri,…

Supernus has resubmitted a New Drug Application to the US Food and Drug Administration for SPN-812, a potential treatment for attention deficit/hyperactivity disorder (ADHD) in pediatric patients. In…